Oncolytics Biotech Company Description

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.

The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.

It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc.

Country	Canada
Founded	1998
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Wayne Pisano

Contact Details

Address: 322 11th Avenue SW Calgary, Alberta T2R 0C5 Canada
Phone	403-670-7377
Website	oncolyticsbiotech.com

Stock Details

Ticker Symbol	ONC
Exchange	Toronto Stock Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA6823108759
SIC Code	2834

Key Executives

Name	Position
Wayne F. Pisano M.B.A.	Interim Chief Executive Officer and Chairman of the Board
Kirk J. Look C.A., CPA	Chief Financial Officer
Dr. Thomas C. Heineman M.D., Ph.D.	Chief Medical Officer
Allison Hagerman P.Eng., P.M.P.	Vice President of Product Development
Amy Goodowitz Levin B.S.N., R.N.	Vice President of Clinical Operations
Jon Patton	Director of Investor Relations and Communication
Christophe Degois	Vice President of Business Development
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.	Consultant